Alto Neuroscience Announces Initiation of Phase 2b Trial for ALTO-207 in Treatment Resistant Depression by Mid-2026

Reuters

Aug 14

<a href="https://laohu8.com/S/ANRO">Alto Neuroscience</a> Announces Initiation of Phase 2b Trial for ALTO-207 in Treatment Resistant Depression by Mid-2026

Alto Neuroscience Inc., a clinical-stage biopharmaceutical company, has announced plans to initiate a potentially pivotal Phase 2b trial for ALTO-207 in patients with treatment-resistant depression by mid-2026. The decision follows promising clinical data and the robust effects of pramipexole observed in the PAX-D study, which supports the therapeutic potential of ALTO-207. Additionally, Alto anticipates reporting topline data from the ALTO-101 Phase 2 proof-of-concept trial for cognitive impairment in schizophrenia in the second half of 2025. Further results from an exploratory study involving ALTO-203 will be presented at a future medical meeting, with subsequent development steps to be determined following a comprehensive analysis of the data.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alto Neuroscience Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250813841679) on August 13, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2559892589"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2559892589\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2559892589?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-14 04:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2559892589","market":"nz","top_or_hot":-1,"title":"Alto Neuroscience Announces Initiation of Phase 2b Trial for ALTO-207 in Treatment Resistant Depression by Mid-2026","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ANRO\">Alto Neuroscience</a> Announces Initiation of Phase 2b Trial for ALTO-207 in Treatment Resistant Depression by Mid-2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Alto Neuroscience Inc., a clinical-stage biopharmaceutical company, has announced plans to initiate a potentially pivotal Phase 2b trial for ALTO-207 in patients with treatment-resistant depression by mid-2026. The decision follows promising clinical data and the robust effects of pramipexole observed in the PAX-D study, which supports the therapeutic potential of ALTO-207. Additionally, Alto anticipates reporting topline data from the ALTO-101 Phase 2 proof-of-concept trial for cognitive impairment in schizophrenia in the second half of 2025. Further results from an exploratory study involving ALTO-203 will be presented at a future medical meeting, with subsequent development steps to be determined following a comprehensive analysis of the data.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alto Neuroscience Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250813841679) on August 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alto Neuroscience Announces Initiation of Phase 2b Trial for ALTO-207 in Treatment Resistant Depression by Mid-2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlto Neuroscience Announces Initiation of Phase 2b Trial for ALTO-207 in Treatment Resistant Depression by Mid-2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-14 04:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ANRO\">Alto Neuroscience</a> Announces Initiation of Phase 2b Trial for ALTO-207 in Treatment Resistant Depression by Mid-2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Alto Neuroscience Inc., a clinical-stage biopharmaceutical company, has announced plans to initiate a potentially pivotal Phase 2b trial for ALTO-207 in patients with treatment-resistant depression by mid-2026. The decision follows promising clinical data and the robust effects of pramipexole observed in the PAX-D study, which supports the therapeutic potential of ALTO-207. Additionally, Alto anticipates reporting topline data from the ALTO-101 Phase 2 proof-of-concept trial for cognitive impairment in schizophrenia in the second half of 2025. Further results from an exploratory study involving ALTO-203 will be presented at a future medical meeting, with subsequent development steps to be determined following a comprehensive analysis of the data.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alto Neuroscience Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250813841679) on August 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250813:nNDLb2G0Xr:1","article_id":"2559892589","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2559892589","pubTimestamp":1755115930,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Alto Neuroscience Inc., a clinical-stage biopharmaceutical company, has announced plans to initiate a potentially pivotal Phase 2b trial for ALTO-207 in patients with treatment-resistant depression by mid-2026. The decision follows promising clinical data and the robust effects of pramipexole observed in the PAX-D study, which supports the therapeutic potential of ALTO-207. Additionally, Alto anticipates reporting topline data from the ALTO-101 Phase 2 proof-of-concept trial for cognitive impairment in schizophrenia in the second half of 2025. Further results from an exploratory study involving ALTO-203 will be presented at a future medical meeting, with subsequent development steps to be determined following a comprehensive analysis of the data.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","ANRO":"Alto Neuroscience Inc"},"translate_title":"Alto Neuroscience宣布到2026年中期启动ALTO-207治疗难治性抑郁症的2b期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANRO":0.9},"content_text":"Alto Neuroscience Announces Initiation of Phase 2b Trial for ALTO-207 in Treatment Resistant Depression by Mid-2026\n    \n\n        Alto Neuroscience Inc., a clinical-stage biopharmaceutical company, has announced plans to initiate a potentially pivotal Phase 2b trial for ALTO-207 in patients with treatment-resistant depression by mid-2026. The decision follows promising clinical data and the robust effects of pramipexole observed in the PAX-D study, which supports the therapeutic potential of ALTO-207. Additionally, Alto anticipates reporting topline data from the ALTO-101 Phase 2 proof-of-concept trial for cognitive impairment in schizophrenia in the second half of 2025. Further results from an exploratory study involving ALTO-203 will be presented at a future medical meeting, with subsequent development steps to be determined following a comprehensive analysis of the data.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alto Neuroscience Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250813841679) on August 13, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}